SCHEMBL6561340

SCHEMBL6561340

CCOc1nc2ccccc2nc1NC(=O)N1CCN(c2cc(F)cc(F)c2)CC1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.46
MAPT P10636 4/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MEN1 O00255 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C19 P33261 1/20 0.44
KMT2A Q03164 1/20 0.44
GLA P06280 2/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HRH4 Q9H3N8 1/20 0.43
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6560420 0.89 KDM4E (0.47) HTR1AMAPTSMN1; SMN2MEN1CYP1A2
SCHEMBL6560436 0.89 MAPT (0.48) MAPTSMN1; SMN2MEN1KMT2AGLA
SCHEMBL6560742 0.89 MAPT (0.48) HTR1AMAPTSMN1; SMN2MEN1CYP1A2
SCHEMBL6559804 0.88 MAPT (0.47) MAPTSMN1; SMN2KMT2AGLAKDM4E
SCHEMBL20893562 0.86 MAPT (0.39) MAPTSMN1; SMN2MEN1CYP1A2CYP3A4
SCHEMBL19457745 0.86 KIT (0.42) HTR1AMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL6562205 0.84 MAPT (0.45) MAPTSMN1; SMN2MEN1CYP1A2CYP3A4
SCHEMBL20893650 0.84 MAPT (0.37) MAPTKDM4EALDH1A1
SCHEMBL20893543 0.83 MAPT (0.40) MAPTMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL19457837 0.83 MAPT (0.42) MAPTSMN1; SMN2MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1075469-B1 PIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF SAMJIN PHARM CO LTD (KR) 2004-05-26 EP disclosed
US-6683184-B2 ANTITUMOR AGENTS SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2004-01-27 US disclosed
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS HTR1A 1259/4885MAPT 4877/4885SMN1; SMN2 2466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.